MedTrace Logo

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

NCT02395640 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 438

Last updated 2021-10-26

No results posted yet for this study

Summary

This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.

Conditions

Interventions

DRUG

Epirubicin

50mg/m2 ivgtt d1

DRUG

Oxaliplatin

DRUG

Capecitabine

1000mg/m2 po d1-14

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2021-02-23
Completion
2021-02-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02395640 on ClinicalTrials.gov